Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors

Cancer

Volumn 83, Issue 6, 1998, Pages 1237-1243

  Kelly, Dympna M ^a   Emre, Sukru ^b   Guy, Stephen R ^b   Miller, Charles M ^b   Schwartz, Myron E ^b   Sheiner, Patricia A ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

De novo malignancies; Immunosuppression; Liver transplant; Nonlymphoid tumors; Recurrent tumor

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; OKT 3; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 0032530608     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1237::AID-CNCR25>3.0.CO;2-5     Document Type: Article

References (28)

1. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncol Hematol 1989;1:27-52.
2. Penn I. Depressed immunity and the development of cancer. Cancer Detect Prev 1994;18:241-52.
3. Selik R, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations and trends. AIDS 1987;1:125.
4. Penn I. The problem of cancer in organ transplant recipients. Transplant Sci 1994;4:23-32.
5. Frei U, Bode U, Repp H, Schindler R, Brunkhorst R, Vogt P, et al. Malignancies under cyclosporine after kidney transplantation. Analysis of a ten year period. Transplant Proc 1993;25:1394-6.
6. Gruber S, Matas AG. Etiology and pathogenesis of tumors occurring after organ transplantation. Transplant Sci 1994;4:87-104.
7. Blohme I, Brynger H. Malignant disease in renal transplant patients. Transplantation 1985;39:23-5.
8. Nalesnik MA, Locker J, Jaffe K, Reyes J, Cooper M, Fung J, et al. Experience with post transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant 1992;6:249-52.
9. Schwanz ME, Sung M, Mor E, Fisher A, Popescu I, Fiel I, et al. A combined surgical/oncological approach to hepatocellular carcinoma in cirrhotic patients. J Am Coll Surg 1995;180:596-603.
10. Penn I. Cancer in the immunosuppressed organ recipient. Transplant Proc 1991;23:1771-2.
11. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BG, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9.
12. Tan-Shalaby J, Tempero M. Malignancies after liver transplantation. A comparative review. Semin Liver Dis 1995;15:156-64.
13. Sheil AGR, Disney APS, Matthew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383-4.
14. Ritters B, Grabensee B, Hearing P. Malignancy under immunosuppression therapy including cyclosporine. Transplant Proc 1994;26:2656-7.
15. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, et al. De novo malignancy following liver transplantation: a single center study. Transplant Proc 1993;25:1397-9.
16. Parker SL, Tong T, Bolden S, Wings PA. Cancer statistics 1996. CA Cancer J Clin 1996;65:5-27.
17. Marcial VA. The role of radiation therapy in the multidisciplinary management of recurrent and metastatic breast cancer. Cancer 1994;74:450-2.
18. Penn I. Kidney transplantation following the treatment of tumors. Transplant Proc 1986;18(Suppl 3):16.
19. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55:742-7.
20. Penn I. Evaluation of a candidate with a previous malignancy. Liver Transplant Surg 1996;2:109-13.
21. Penn I. The changing pattern of post transplant malignancies. Transplant Proc 1991;23:1101-3.
22. Nalesnik MA, Demetris AJ, Fung JJ, Starzl TE. Lymphoproliferative disorders arising under immunosuppression with FK506: initial observations in a large transplant population. Transplant Proc 1991;23:1108-10.
23. Jain AB, Yee L, Nalesnik M, Fung JJ, et al. De novo non lymphoid malignancies following 1000 consecutive liver transplantations under tacrolimus. Presented at ASTP Scientific Program, Dallas, Texas, May 26-29, 1996.
24. Swinnen LJ, Costanzo-Norden MK, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723-8.
25. Batiuk TD, Barry JM, Bennett WM, Meyer MM, Tolzman D, Norman DJ. Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants. Transplant Proc 1993;25:1391.
26. Bleday R, Lee E, Jessurun J, Heine J, Wong D. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993;36:908-12.
27. Wolke AM, Schaffner F, Kapelman B, Sacks HS. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med 1984;76:1075-8.
28. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80:1141-50.